Cellular Dynamics partners with Roche in deal worth up to $83 million

Freeman Staff

Nov. 10, 2015

MADISON — Cellular Dynamics International, Inc. announced an agreement Tuesday to supply induced pluripotent stem cell (iPSC)-derived iCell products to Roche with the potential partnership value at $83 million.

The iCell products will be used for the identification of novel drug candidates. According to the announcement, under the terms of the supply and license agreement, Roche will have exclusive access to specific iCell products to be employed in High Throughput Screening and lead optimization for drug discovery. The partnership is dependent on certain development milestones and may amount to $83 million in total.

“Our partnerships with established leaders in the pharmaceutical industry, now including Roche, demonstrate that CDI products are increasingly becoming important tools for efficient drug discovery,” said Kaz Hirao, CDI Chairman and CEO, in a statement. “This agreement is the largest single collaboration for CDI to date. We look forward to a productive working relationship with Roche that will show how iPSC-derived cells can help generate a large number of early product candidates.”